Remedy Entertainment’s interim CEO Markus Mäki has confirmed the studio’s upcoming adventure game Control Resonant does not use generative AI, with the game instead being built by human creativity and ideas.
The detail was shared during a recent company earnings call (via Game Developer), where Mäki described the importance of player value, and ‘doing things that really add something to the gameplay experience and the player experience’.
Remedy Entertainment and GenAI – quick links
Remedy Entertainment’s stance on GenAI
It’s typically in these presentations that questions around GenAI arise, as company investors tend to be bullish about new technology implementation, particularly when it pertains to perceived efficiencies or cost-savings.
As Mäki made clear in his response, Remedy Entertainment is primarily concerned with making its games compelling and creative for players, and while there is ‘varied interest in different crafts at Remedy into investigating these AI tools’, the company is not currently implementing them into its game development processes.
Control Resonant is completely GenAI free, and will remain so during the final stages of development.
Mäki did not completely rule out the future use of GenAI at Remedy Entertainment, however, taking a more neutral stance to account for potential newer developments, which could be ‘right’ for the studio.
‘Making far-reaching promises about the future is pretty hard at this point,’ Mäki said. ‘We are actively following the development [of GenAI] and seeing if there is anything that is really ethically in the right place, and is something that can add player value and that our teams want to use. Then, of course, that’s an easier decision.’
As Mäki said, for Remedy Entertainment, it’s both player value and ethics that will be important to the future implementation of GenAI in games at the company.
GenAI remains a major issue for game developers and studios
Mäki’s stance appears fairly reasonable, and in line with statements made by many other prominent games companies.
The reality is GenAI is not currently suitable for most circumstances, particularly in game development, where copyright challenges are the least of the worries.
One of the bigger issues is player reception, as many video game players – particularly those who engage with popular IP online – are fiercely critical of GenAI implementation, and how it diminishes the quality of games, as well as the human input.
Larian Studios, developer of Baldur’s Gate 3, recently found this out the hard way, after CEO Swen Vincke discussed his enthusiasm for GenAI and its potential time-saving for future Larian-made games like Divinity.
For weeks after this mention of the use of GenAI for development concepts, Vincke and the entire Larian Studios team were bombarded by criticism, from players concerned by the use of GenAI and its erasure of human talent, seeing it as a perceived betrayal of the company’s core values of elevating creativity and passion.
Eventually, Vincke was forced to address the backlash in a statement that confirmed Larian would no longer use GenAI tools during concept art development.
It’s likely Remedy Entertainment – and other studios observing the discourse – is keenly aware of public sentiment, and how the use of GenAI can reshape perceptions and enthusiasm for upcoming games.
Remedy Entertainment awaits new CEO in March
Notably, in the same earnings showcase where Mäki discussed the implementation of GenAI at Remedy Entertainment, it was also confirmed the studio will get a new CEO, Jean-Charles Gaudechon, in March.
Gaudechon was formerly at Electronic Arts and CCP Games, where he held various leadership positions in charge of profit and loss.
‘I am delighted to announce the appointment of Jean-Charles (JC) Gaudechon to lead Remedy into a phase of profitable growth,’ Henri Österlund, Chairman of the Board of Directors, said.
‘Under JC’s leadership, we are well-positioned to significantly accelerate growth, guide Remedy towards greater independence through self-publishing, and deliver sustained value to our players, partners and shareholders.’
Gaudechon takes over from Mäki as interim CEO, with the changes following the departure of Tero Virtala, who stepped down in 2025 after nine years leading the company.
It’s unclear whether Gaudechon shares Mäki’s caution around GenAI use at the company, but we are likely to hear more from Remedy as the dust settles.
